-+ 0.00%
-+ 0.00%
-+ 0.00%

Cardiol Therapeutics Hits 50% Enrollment in Phase III MAVERIC Trial for Recurrent Pericarditis

Reuters·01/13/2026 12:28:06

Please log in to view news